Technology

Anavex

$6.16
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.36 (+6.26%) Today
+$0.05 (+0.82%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Anavex and other stocks, options, and ETFs commission-free!

About AVXL

Anavex Life Sciences Corp. Common Stock, also called Anavex, is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY. The listed name for AVXL is Anavex Life Sciences Corp. Common Stock.

CEO
Christopher U. Missling
Employees
20
Headquarters
New York, New York
Founded
2004
Market Cap
414.12M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
714.68K
High Today
$6.14
Low Today
$5.67
Open Price
$5.67
Volume
1.08M
52 Week High
$7.69
52 Week Low
$2.20

Collections

AVXL Earnings

-$0.17
-$0.11
-$0.06
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected Feb 4, Pre-Market

You May Also Like

IPOE=
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure